Abstract

Simple SummaryBone metastasis is a debilitating, incurable complication that occurs in breast cancer patients with a variable period of latency after treatment of the primary tumor. The seeding of individual cancer cells in the bone marrow from the primary tumor occurs early in disease progression. How disseminated cancer cells are able to remain dormant in the bone marrow and then reactivate decades later to form destructive bone lesions is not fully understood. We have used model systems to identify bone resident cell types, and molecular mediators, that influence the survival and fate of disseminated breast cancer cells. The identification of such cellular and molecular support mechanisms can inform the design of new therapeutic strategies aimed at eliminating indolent cancer cells from the bone marrow, preventing progression to overt metastases.Metastatic breast cancer in bone is incurable and there is an urgent need to develop new therapeutic approaches to improve survival. Key to this is understanding the mechanisms governing cancer cell survival and growth in bone, which involves interplay between malignant and accessory cell types. Here, we performed a cellular and molecular comparison of the bone microenvironment in mouse models representing either metastatic indolence or growth, to identify mechanisms regulating cancer cell survival and fate. In vivo, we show that regardless of their fate, breast cancer cells in bone occupy niches rich in osteoblastic cells. As the number of osteoblasts in bone declines, so does the ability to sustain large numbers of breast cancer cells and support metastatic outgrowth. In vitro, osteoblasts protected breast cancer cells from death induced by cell stress and signaling via gap junctions was found to provide important juxtacrine protective mechanisms between osteoblasts and both MDA-MB-231 (TNBC) and MCF7 (ER+) breast cancer cells. Combined with mathematical modelling, these findings indicate that the fate of DTCs is not controlled through the association with specific vessel subtypes. Instead, numbers of osteoblasts dictate availability of protective niches which breast cancer cells can colonize prior to stimulation of metastatic outgrowth.

Highlights

  • The spread of cancer cells to the bone marrow occurs frequently during breast cancer progression [1,2] and significantly increases the risk of skeletal recurrence [2]

  • We show that the ability of the bone microenvironment to support large numbers of disseminated tumor cells (DTCs) declines when the number of osteoblastic cells is reduced during skeletal maturation

  • If breast cancer cells arriving in human bone need osteoblastic cells to survive, this might partly explain the inefficiency of the metastatic process and the diffuse multi-focal pattern of skeletal metastases observed in patients

Read more

Summary

Introduction

The spread of cancer cells to the bone marrow occurs frequently during breast cancer progression [1,2] and significantly increases the risk of skeletal recurrence [2]. The mechanisms that influence the survival and fate of disseminated tumor cells (DTCs) in bone during this period of metastatic dormancy are not fully understood but remain an attractive therapeutic target. Following their dissemination to bone, tumor cells are proposed to reside in hematopoietic stem cell (HSC) niches located in proximity to blood vessels (perivascular), bone surfaces (endosteal) or both (overlapping) [3,4,5]. Osteoblasts, derived from mesenchymal stromal/stem cells (MSCs), are the key cell type responsible for bone formation During their differentiation in bone, these cells can reside in both perivascular and endosteal niches, where they regulate HSC activity [11,12]. The specific roles of osteoblastic cells and different types of vessels in controlling the survival of DTCs in bone during metastatic dormancy and outgrowth are not fully understood

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call